NEW YORK, Sept. 08, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of The Advisory Board Company (NASDAQ:ABCO) from January 21, 2015 through February 23, 2016, inclusive (the “Class Period”) of the important October 2, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Advisory Board investors under the federal securities laws.
To join the Advisory Board class action, go to http://rosenlegal.com/cases-1180.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The complaint alleges that defendants during the Class Period made materially false and misleading statements and/or failed to disclose that there were severe integration problems associated with Advisory Board’s acquisition of Royall and, as a consequence of these integration problems, defendants had no basis to increase the revenue guidance for Royall during the Class Period. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 2, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1180.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Italy Fines Apple €98.6 Million Over App Store Dominance
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



